Landscape with 4 parachutes, heading to a steady A1C goal

A long-acting basal insulin indicated to improve glycemic control in adults with diabetes.


Adult patients who miss a dose of Tresiba® should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule. Ensure that at least 8 hours have elapsed between Tresiba® injections.1


Landscape with 4 parachutes, heading to a steady A1C goal

Eligible patients pay no more than $15 per prescriptiona

Explore the features of the 2 Tresiba® FlexTouch® pens

Log in to request Tresiba® FlexTouch® samplesb

aFor up to 24 months. Maximum savings of $500 per prescription. Eligibility and other restrictions apply.

bYou must be a licensed practitioner who can legally prescribe medication in your state. (Request for product samples is limited to 1 request per health care professional.)


BEGIN™: Low Volume study design

A 26-week, randomized, open-label, multicenter trial in insulin-naïve adults with type 2 diabetes comparing the efficacy and safety of once-daily Tresiba® U-200 (n=228) and once-daily insulin glargine U-100 (n=229) + metformin +/- dipeptidyl peptidase-4 (DPP-4) inhibitor. Basal insulin was titrated weekly to a fasting plasma glucose (FPG) target of 70 to 90 mg/dL according to mean prebreakfast self-measured blood glucose (SMBG) values (mean of 3 consecutive days). Primary endpoint was change in A1C from baseline after 26 weeks of treatment (noninferiority margin of 0.4% was met). Tresiba® A1C reduction from baseline at end of study: 1.18%.1,2



Schedules change. For adults, dose timing can too.

Once-daily Tresiba® offers continued efficacy for your adult patients
even if a dose is delayed or schedules change.1


Once-daily basal insulin Tresiba® U-200 FlexTouch® pen

Adult patients who miss a dose of Tresiba® should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule. Ensure that at least 8 hours have elapsed between Tresiba® injections.1



Tresiba® has a half-life of approximately 25 hours at steady state1




See how Tresiba® compares with insulin glargine U-100




Once-daily Tresiba® has a flat and stable profile1,3,4



Adult patients who miss a dose of Tresiba® (insulin degludec 100 Units/mL, 200 Units/mL) should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule. Ensure that at least 8 hours have elapsed between Tresiba® injections.1

Selected Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening

Tresiba® (insulin degludec injection) Indications and Usage

Tresiba® (insulin degludec injection) is indicated to improve glycemic control in adults with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine)

Please click here for Prescribing Information.

 

References:

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; December 2016.
  2. Gough SCL, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Diabetes Care. 2013;36(9):2536-2542.
  3. Heise T, Korsatko S, Nosek L, et al. J Diabetes. 2016;8(1):132-138.
  4. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Diabetes Obes Metab. 2012;14(9):859-864.